Novel targets and emerging therapies in MPM

Ioannis Gkiozos (Athens, Greece)

Source: ERS Skills course: Multi-disciplinary care in thoracic oncology

Number: 19

Disease area: -

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ioannis Gkiozos (Athens, Greece). Novel targets and emerging therapies in MPM. ERS Skills course: Multi-disciplinary care in thoracic oncology

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017
Novel therapeutics for CF Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission Year: 2019
Proteases as tools for diagnosis and novel therapeutics Source: ERS Research Seminar 2015 Year: 2015
Malignant mesothelioma: new treatment advances, including targeted therapies Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care Year: 2021
From anti-PD1/L1 inhibitors to new immunotherapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018
Potential of regulatory T-cell-based therapies in the management of severe COVID-19 Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020 Year: 2020
Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008
New molecular-directed therapies for mesothelioma: have there been any advances? Source: International Congress 2014 – Mesothelioma: a never-ending story Year: 2014
Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007
How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021
Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017
Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004
Targeting targeted therapies: more choices and the best sequences Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019